Juno Therapeutics, Inc. (JUNO) Shares Sold by Brighton Jones LLC
Brighton Jones LLC lowered its stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 14.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,444 shares of the biopharmaceutical company’s stock after selling 1,240 shares during the period. Brighton Jones LLC’s holdings in Juno Therapeutics were worth $334,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Teachers Advisors LLC increased its stake in shares of Juno Therapeutics by 15.4% during the 2nd quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after purchasing an additional 9,890 shares during the last quarter. State Street Corp increased its stake in shares of Juno Therapeutics by 7.4% during the 2nd quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock worth $96,742,000 after purchasing an additional 222,754 shares during the last quarter. QS Investors LLC purchased a new stake in shares of Juno Therapeutics during the 2nd quarter worth approximately $135,000. Northern Trust Corp increased its stake in shares of Juno Therapeutics by 11.8% during the 2nd quarter. Northern Trust Corp now owns 382,631 shares of the biopharmaceutical company’s stock worth $11,438,000 after purchasing an additional 40,468 shares during the last quarter. Finally, Wasatch Advisors Inc. purchased a new stake in shares of Juno Therapeutics during the 2nd quarter worth approximately $19,787,000. Institutional investors own 66.96% of the company’s stock.
Several equities research analysts have recently issued reports on JUNO shares. Vetr lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.85 price target for the company. in a research note on Monday, July 24th. Zacks Investment Research lowered shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Morgan Stanley lifted their price objective on shares of Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a research note on Monday, August 7th. BTIG Research upgraded shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a research note on Monday, August 28th. Finally, Wedbush upgraded shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price objective for the company in a research note on Tuesday, August 29th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $44.20.
In other news, Director Richard Klausner sold 12,000 shares of Juno Therapeutics stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $42.66, for a total transaction of $511,920.00. Following the completion of the sale, the director now directly owns 783,536 shares of the company’s stock, valued at approximately $33,425,645.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Robert Azelby sold 12,869 shares of Juno Therapeutics stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $39.95, for a total transaction of $514,116.55. Following the sale, the executive vice president now directly owns 50,289 shares of the company’s stock, valued at $2,009,045.55. The disclosure for this sale can be found here. Over the last three months, insiders sold 79,670 shares of company stock valued at $3,553,777. Insiders own 15.26% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Shares Sold by Brighton Jones LLC” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/11/21/juno-therapeutics-inc-juno-shares-sold-by-brighton-jones-llc.html.
Shares of Juno Therapeutics, Inc. (JUNO) traded up $0.42 during trading hours on Tuesday, reaching $59.06. 1,202,700 shares of the company’s stock traded hands, compared to its average volume of 2,055,642. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics, Inc. has a 1 year low of $17.52 and a 1 year high of $61.59.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. During the same period last year, the firm earned ($0.57) EPS. The business’s quarterly revenue was up 115.4% compared to the same quarter last year. equities analysts expect that Juno Therapeutics, Inc. will post -4.02 earnings per share for the current fiscal year.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.